Lv1
60 积分 2021-03-07 加入
Abstract CT147: Phase I clinical study of Bruton’s tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
1年前
已关闭
First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)
1年前
已关闭
Ene Reactions
1年前
已完结
Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review
2年前
已完结
Pirtobrutinib: First Approval
2年前
已完结
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
2年前
已完结
MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
2年前
已完结
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
2年前
已完结
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
4年前
已完结
Targeted protein degraders crowd into the clinic
4年前
已完结
皖公网安备34019202002308
